Approximately 170 million people suffer from hepatitis C, but that number may on the way down in light of recent data. British researchers at Oxford University have published promising research about a vaccine to protect against hepatitis C in the journal Science Translational Medicine.
While this vaccine is still in the early stages of development, Oxford University scientists said that results from the first human trials were promising. In fact, study participants demonstrated the same response as individuals who have a natural immunity to the infectious disease.
At the Liver Institute of Virginia, which has two offices on the campus of Bon Secours Mary Immaculate Hospital in Newport News, Virginia and at Bon Secours St. Mary’s Hospital in Richmond, Virginia, world-renowned liver disease treatment specialist, Dr. Mitchell Shiffman, and his expert team treat Hampton Roads residents struggling with liver diseases, including hepatitis C, hepatitis B, and liver cancer.
While Dr. Shiffman is currently running numerous clinical trials at his Newport News office, he is excited about the new research and looks forward to the next stage of trials. According to the Oxford team, a U.S. team of researchers is planing to carry out a larger trial of the vaccine in at-risk groups. “We can currently treat hepatitis C sufferers with a variety of methods,” notes Dr. Shiffman, “but the development of a hepatitis C vaccine, to join the hepatitis A and hepatitis b vaccine, would be crucial in helping at-risk patients avoid the disease in the first place.”
Source: FoxNews.com, Hepatitis C Vaccine Trials a Success, Scientists Say